ArticleOpen biology2013
Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds.
Article in Open biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Bioprospecting Honey-Derived Microorganisms for the Biological Control of Phytopathogens.Microorganisms · 2026Article
- Automating the practice of science: Opportunities, challenges, and implications.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- An experimental target-based platform in yeast for screening Plasmodium vivax deoxyhypusine synthase inhibitors.PLoS neglected tropical diseases · 2024Article
- An automated positive selection screen in yeast provides support for boron-containing compounds as inhibitors of SARS-CoV-2 main protease.Microbiology spectrum · 2024Article
- Selective Inhibition of Plasmodium falciparum ATPase 6 by Artemisinins and Identification of New Classes of Inhibitors after Expression in Yeast.Antimicrobial agents and chemotherapy · 2022Article
- A hundred spotlights on microbiology: how microorganisms shape our lives.Microbial cell (Graz, Austria) · 2022Article
- Accelerating high-throughput virtual screening through molecular pool-based active learning.Chemical science · 2021Article
- Structural features and development of an assay platform of the parasite target deoxyhypusine synthase of Brugia malayi and Leishmania major.PLoS neglected tropical diseases · 2020Article
- Two flavonoid-based compounds fromJournal of microbiology and biotechnology · 2020Article
- Potential use of Pichia pastoris strain SMD1168H expressing DNA topoisomerase I in the screening of potential anti‑breast cancer agents.Molecular medicine reports · 2019Article
- Self-Establishing Communities: A Yeast Model to Study the Physiological Impact of Metabolic Cooperation in Eukaryotic Cells.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Yeast Systems Biology: The Continuing Challenge of Eukaryotic Complexity.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Development of a high throughput yeast-based screening assay for human carbonic anhydrase isozyme II inhibitors.AMB Express · 2018Article
- Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.PLoS neglected tropical diseases · 2018Article
- Identifying inhibitors of the Leishmania inositol phosphorylceramide synthase with antiprotozoal activity using a yeast-based assay and ultra-high throughput screening platform.Scientific reports · 2018Article
- Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan.Scientific reports · 2018Article
- Yeast-Based High-Throughput Screens to Identify Novel Compounds Active against Brugia malayi.PLoS neglected tropical diseases · 2016Article
- Article
- Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases.Journal of the Royal Society, Interface · 2015Article
- A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.Disease models & mechanisms · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
We have developed a robust, fully automated anti-parasitic drug-screening method that selects compounds specifically targeting parasite enzymes and not their host counterparts, thus allowing the early elimination of compounds with potential side effects. Our yeast system permits multiple parasite targets to be assayed in parallel owing to the strains' expression of different fluorescent proteins. A strain expressing the human target is included in the multiplexed screen to exclude compounds that do not discriminate between host and parasite enzymes. This form of assay has the advantages of using known targets and not requiring the in vitro culture of parasites. We performed automated screens for inhibitors of parasite dihydrofolate reductases, N-myristoyltransferases and phosphoglycerate kinases, finding specific inhibitors of parasite targets. We found that our 'hits' have significant structural similarities to compounds with in vitro anti-parasitic activity, validating our screens and suggesting targets for hits identified in parasite-based assays. Finally, we demonstrate a 60 per cent success rate for our hit compounds in killing or severely inhibiting the growth of Trypanosoma brucei, the causative agent of African sleeping sickness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.